Merck and Vioxx. (A), Should the company continue to battle each of the 27,000 lawsuits filed against it? / Jaan Elias, Spencer Hutchins, Andrea Nagy, Constance E. Bagley & Douglas W. Rae.

Format:

Book

Author/Creator:

Elias, Jaan, author.

Hutchins, Spencer, author.

Nagy, Andrea, author.

Bagley, Constance E., author.

Rae, Douglas W., author.

Series:

SAGE knowledge. Cases.

SAGE Knowledge. Cases.

SAGE knowledge. Cases

Language:

English

Subjects (All):

Merck & Co.

Crisis management--Case studies.

Crisis management.

Actions and defenses--Case studies.

Actions and defenses.

Genre:

Case studies.

Physical Description:

1 online resource : illustrations (black and white, and colour).

Place of Publication:

[London] : SAGE, 2016.

System Details:

text file

Summary:

Over the years, Merck & Co. built an enviable reputation not just as a paragon of the pharmaceutical industry but as one of America's most admired businesses. However, after withdrawing its blockbuster drug Vioxx in September of 2004, Merck found its reputation and its financial stability in danger. The day after the announcement, Merck's stock plunged 30% and a few analysts even wondered if Merck would be forced into bankruptcy. This study looks at the processes that Merck would need to go through before achieving stability.

Notes:

Originally Published in: Elias, J., Hutchins, S., Nagy, A., Bagley, C. E., & Rae, D. W. (2008). Merck and Vioxx (A): Should the Company Continue to Battle Each of the 27,000 Lawsuits Filed Against It? 08-016. New Haven, CT: Yale School of Management, Yale University.

No ILL or scholarly sharing allowed.

Description based on online resource; title from home page (viewed on May 3, 2016).

ISBN:

9781473973350

OCLC:

1017731210

Access Restriction:

Restricted for use by site license.